European Registry on the Management of Helicobacter Pylori Infection

NCT02328131 | Recruiting

• 1 other identifier: Hp-EuReg
• Study Type: observational
• Target: 10,000
• Locations: 28 countries
• Sites: 28

Brief Summary

The great diversity of regimens and treatment lines, the different efficacy of these, mostly due to the increase in bacterial antibiotic resistance and regional differences, requires a continuous critical analysis of clinical practice, evaluating systematically the efficacy and safety of the different regimens and the cost-effectiveness of the different diagnostic-therapeutic strategies. This will help in the design of an efficient and optimized treatment that will reduce number of re-treatments, diagnostic tests and the appearance of associated pathologies such as peptic ulcers, gastrointestinal bleeding and, probably, gastric cancers. Therefore, the evaluation of real clinical practice using non-interventionist registries will help to improve the design and organization of European Consensus on the management of H. pylori infection, which is the best way to establish healthcare efficiency. Primary aim To obtain a database registering systematically over a year a large and representative sample of routine clinical practice of European gastroenterologists in order to produce descriptive studies of the management of H. pylori infection. Secondary aims

1. 1.To evaluate H. pylori infection consensus and clinical guidelines implementation in different countries.
2. 2.To perform studies focused on epidemiology, efficacy and safety of the commonly used treatments to eradicate H. pylori.
3. 3.To evaluate accessibility to healthcare technologies and drugs used in the management of H. pylori infection.
4. 4.To allow the development of partial and specific analysis by the participating researchers after approval by the Registry's Scientific Committee

Conditions

H. Pylori Infection

Outcome Measures

Primary Outcomes (1)

• Prescribed treatment for H. pylori

  * Drugs * Dosage and intakes * Length of treatment

  1 year

Secondary Outcomes (3)

• Adverse Events

  1 year

• Efficacy of treatment

  1 year

• Anonymised patient identifiers

  1 year

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Infected adult patients by Helicobacter pylori

You may qualify if:

• Infected adult patients by Helicobacter pylori

Sponsors & Collaborators

• Javier P. Gisbert: lead

Study Sites (30)

Medical University Wien

Vienna, Austria

RECRUITING

CHU de Charleroi, Charleroi

Charleroi, Belgium

RECRUITING

Medical University of Sofia

Sofia, Bulgaria

RECRUITING

University Hospital Merkur

Zagreb, Croatia

RECRUITING

Charles University Faculty of Medicine

Prague, Czechia

RECRUITING

Køge University Hospital

Køge, Denmark

RECRUITING

University of Tartu

Tartu, Estonia

RECRUITING

Herttoniemi Hospital, Helsinki

Helsinki, Finland

RECRUITING

Hôpital Pellegrin

Bordeaux, France

RECRUITING

Medizin Uni Magdeburg

Magdeburg, Germany

RECRUITING

Gastroenterology Clinic, Henry Dunant Hospital

Athens, Greece

RECRUITING

Ferencváros Health Centre, Gaastroenterology

Budapest, Hungary

RECRUITING

Adelaide Meath Hospital, Dublin

Dublin, Ireland

RECRUITING

Studio Gasbarrini

Roma, Italy

RECRUITING

Digestive Diseases Centre GASTRO

Riga, Latvia

RECRUITING

Lithuanian university of Health Sciences Hospital

Kaunas, Lithuania

RECRUITING

Ikazia Ziekenhuis/ Erasmus Medisch Centrum

Rotterdam, Netherlands

RECRUITING

Central Hospital of Ostfold

Fredrikstad, Norway

RECRUITING

Departament of Gastroenterology, Medical Centre for Postgraduate Education

Warsaw, Poland

RECRUITING

Porto

Porto, Portugal

RECRUITING

Timisoara

Timișoara, Romania

RECRUITING

Central Scientific Research Institute of Gastroenterology

Moscow, Russia

RECRUITING

Clinical Center of Serbia

Belgrade, Serbia

RECRUITING

DC Rogaska

Rogaška Slatina, Slovenia

RECRUITING

Hospital de La Princesa, Madrid

Madrid, Spain

RECRUITING

Uppsala University Hospital.

Uppsala, Sweden

RECRUITING

University Hospital Basel

Basel, Switzerland

RECRUITING

Dokuz Eylul University School of Medicine

Izmir, Turkey (Türkiye)

RECRUITING

National Medical University

Kiev, Ukraine

RECRUITING

Leeds General Infirmiry Hospital

Leeds, United Kingdom

RECRUITING

Related Publications (36)

• Arkkila PE, Seppala K, Kosunen TU, Sipponen P, Makinen J, Rautelin H, Farkkila M. Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers. Eur J Gastroenterol Hepatol. 2005 Jan;17(1):93-101. doi: 10.1097/00042737-200501000-00018.

  PMID: 15647648 BACKGROUND

• Azevedo NF, Huntington J, Goodman KJ. The epidemiology of Helicobacter pylori and public health implications. Helicobacter. 2009 Sep;14 Suppl 1:1-7. doi: 10.1111/j.1523-5378.2009.00703.x.

  PMID: 19712161 BACKGROUND

• Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther. 2003 Jan;17(1):99-109. doi: 10.1046/j.1365-2036.2003.01396.x.

  PMID: 12492738 BACKGROUND

• de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008 Apr;134(4):945-52. doi: 10.1053/j.gastro.2008.01.071. Epub 2008 Jan 30.

  PMID: 18395075 BACKGROUND

• Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol. 2003 Jun;17 Suppl B:36B-40B. doi: 10.1155/2003/714124.

  PMID: 12845349 BACKGROUND

• Ford AC, Axon AT. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter. 2010 Sep;15 Suppl 1:1-6. doi: 10.1111/j.1523-5378.2010.00779.x.

  PMID: 21054646 BACKGROUND

• Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther. 2011 Dec;34(11-12):1255-68. doi: 10.1111/j.1365-2036.2011.04887.x. Epub 2011 Oct 21.

  PMID: 22017749 BACKGROUND

• Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010 May-Jun;44(5):313-25. doi: 10.1097/MCG.0b013e3181c8a1a3.

  PMID: 20054285 BACKGROUND

• Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther. 2011 Sep;34(6):604-17. doi: 10.1111/j.1365-2036.2011.04770.x. Epub 2011 Jul 11.

  PMID: 21745241 BACKGROUND

• Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Munoz JE. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev. 2004;(2):CD004062. doi: 10.1002/14651858.CD004062.pub2.

  PMID: 15106235 BACKGROUND

• Graham DY, Rimbara E. Understanding and appreciating sequential therapy for Helicobacter pylori eradication. J Clin Gastroenterol. 2011 Apr;45(4):309-13. doi: 10.1097/MCG.0b013e31820ac05e.

  PMID: 21389810 BACKGROUND

• Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010 Aug;59(8):1143-53. doi: 10.1136/gut.2009.192757. Epub 2010 Jun 4.

  PMID: 20525969 BACKGROUND

• Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC, Meza-Montenegro MM, Pena R, Pena EM, Salazar-Martinez E, Correa P, Martinez ME, Valdivieso M, Goodman GE, Crowley JJ, Baker LH. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011 Aug 6;378(9790):507-14. doi: 10.1016/S0140-6736(11)60825-8. Epub 2011 Jul 21.

  PMID: 21777974 BACKGROUND

• Hsu PI, Wu DC, Wu JY, Graham DY. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter. 2011 Apr;16(2):146-52. doi: 10.1111/j.1523-5378.2011.00829.x.

  PMID: 21435093 BACKGROUND

• Ikenberry SO, Harrison ME, Lichtenstein D, Dominitz JA, Anderson MA, Jagannath SB, Banerjee S, Cash BD, Fanelli RD, Gan SI, Shen B, Van Guilder T, Lee KK, Baron TH; ASGE STANDARDS OF PRACTICE COMMITTEE. The role of endoscopy in dyspepsia. Gastrointest Endosc. 2007 Dec;66(6):1071-5. doi: 10.1016/j.gie.2007.07.007. Epub 2007 Oct 29. No abstract available.

  PMID: 18028927 BACKGROUND

• Maconi G, Sainaghi M, Molteni M, Bosani M, Gallus S, Ricci G, Alvisi V, Porro GB. Predictors of long-term outcome of functional dyspepsia and duodenal ulcer after successful Helicobacter pylori eradication--a 7-year follow-up study. Eur J Gastroenterol Hepatol. 2009 Apr;21(4):387-93. doi: 10.1097/MEG.0b013e3283069db0.

  PMID: 19182682 BACKGROUND

• Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012 May;61(5):646-64. doi: 10.1136/gutjnl-2012-302084.

  PMID: 22491499 BACKGROUND

• McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med. 2010 Apr 29;362(17):1597-604. doi: 10.1056/NEJMcp1001110. No abstract available.

  PMID: 20427808 BACKGROUND

• McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012 Sep;36(5):414-25. doi: 10.1111/j.1365-2036.2012.05211.x. Epub 2012 Jul 15.

  PMID: 22803691 BACKGROUND

• Moayyedi P. The health economics of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol. 2007;21(2):347-61. doi: 10.1016/j.bpg.2006.11.004.

  PMID: 17382282 BACKGROUND

• Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol. 2003 Dec;98(12):2621-6. doi: 10.1111/j.1572-0241.2003.08724.x.

  PMID: 14687807 BACKGROUND

• Niv Y, Hazazi R. Helicobacter pylori recurrence in developed and developing countries: meta-analysis of 13C-urea breath test follow-up after eradication. Helicobacter. 2008 Feb;13(1):56-61. doi: 10.1111/j.1523-5378.2008.00571.x.

  PMID: 18205667 BACKGROUND

• Oderda G, Shcherbakov P, Bontems P, Urruzuno P, Romano C, Gottrand F, Gomez MJ, Ravelli A, Gandullia P, Roma E, Cadranel S, De Giacomo C, Canani RB, Rutigliano V, Pehlivanoglu E, Kalach N, Roggero P, Celinska-Cedro D, Drumm B, Casswall T, Ashorn M, Arvanitakis SN; European Pediatric Task Force on Helicobacter pylori. Results from the pediatric European register for treatment of Helicobacter pylori (PERTH). Helicobacter. 2007 Apr;12(2):150-6. doi: 10.1111/j.1523-5378.2007.00485.x.

  PMID: 17309752 BACKGROUND

• Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol. 2009 Jan;104(1):21-5. doi: 10.1038/ajg.2008.87.

  PMID: 19098844 BACKGROUND

• Tepes B, Denkovski M, Jurecic NB, Tepes K, Cano-Catala A, Parra P, Moreira L, Nyssen OP, Megraud F, O'Morain C, Gisbert JP. Second- and Third-Line Therapies for Helicobacter pylori Eradication in Slovenia: Data From 2013-2023 of the European Registry on H. pylori Management. Helicobacter. 2025 Sep-Oct;30(5):e70085. doi: 10.1111/hel.70085.

  PMID: 41168889 DERIVED

• Tepes B, Jurecic NB, Denkovski M, Vujasinovic M, Kikec Z, Bednarik J, Tepes K, Cano-Catala A, Parra P, Moreira L, Nyssen OP, Megraud F, O'Morain C, Gisbert JP. First-Line Therapy for Helicobacter pylori in Slovenia: Data From 2013 to 2023 of the European Registry on H. pylori Management. Helicobacter. 2025 Mar-Apr;30(2):e70029. doi: 10.1111/hel.70029.

  PMID: 40178062 DERIVED

• Tejedor-Tejada J, Martinez-Dominguez SJ, Hernandez L, Cano-Catala A, Parra P, Moreira L, Nyssen OP, Gisbert JP; Hp-EuReg Investigators. Management of Helicobacter pylori Infection in Spain Beyond the Data Collected in the European Registry on H. pylori Management (Hp-EuReg): Results of a Nationwide Survey. Helicobacter. 2025 Mar-Apr;30(2):e70028. doi: 10.1111/hel.70028.

  PMID: 40167351 DERIVED

• Casas Deza D, Alcedo J, Lafuente M, Lopez FJ, Perez-Aisa A, Pavoni M, Tepes B, Jonaitis L, Castro-Fernandez M, Pabon-Carrasco M, Keco-Huerga A, Voynovan I, Bujanda L, Lucendo AJ, Brglez Jurecic N, Denkovski M, Vologzanina L, Rodrigo L, Martinez-Dominguez SJ, Fadieienko G, Huguet JM, Abdulkhakov R, Abdulkhakov SR, Alcaide N, Velayos B, Hernandez L, Bordin DS, Gasbarrini A, Kupcinskas J, Babayeva G, Gridnyev O, Leja M, Rokkas T, Marcos-Pinto R, Lerang F, Boltin D, Mestrovic A, Smith SM, Venerito M, Boyanova L, Milivojevic V, Doulberis M, Kunovsky L, Parra P, Cano-Catala A, Moreira L, Nyssen OP, Megraud F, Morain CO, Gisbert JP; Hp-EuReg investigators. Probiotics Prescribed With Helicobacter pylori Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the European Registry on Helicobacter pylori Management (Hp-EuReg). Am J Gastroenterol. 2025 Nov 1;120(11):2644-2659. doi: 10.14309/ajg.0000000000003351. Epub 2025 Feb 4.

  PMID: 39902822 DERIVED

• Olmedo L, Calvet X, Gene E, Bordin DS, Voynovan I, Castro-Fernandez M, Pabon-Carrasco M, Keco-Huerga A, Perez-Aisa A, Lucendo AJ, Rodrigo L, Sarsenbaeva AS, Khlinov IB, Fadieienko G, Zaytsev O, Lanas A, Martinez-Dominguez SJ, Alfaro E, Jonaitis L, Nunez O, Pellicano R, Hernandez L, Gridnyev O, Kupcinskas J, Gasbarrini A, Boltin D, Niv Y, Babayeva G, Marcos-Pinto R, Tepes B, Venerito M, Papp V, Lerang F, Leja M, Phull PS, Marlicz W, Doulberis M, Smith SM, Milivojevic V, Kunovsky L, Mestrovic A, Matysiak-Budnik T, Simsek H, Cano-Catala A, Puig I, Moreira L, Parra P, Nyssen OP, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg investigators*. Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg). Gut. 2024 Dec 10;74(1):15-25. doi: 10.1136/gutjnl-2024-332804.

  PMID: 39461739 DERIVED

• Martinez-Dominguez SJ, Nyssen OP, Lanas A, Alfaro E, Jonaitis L, Mahmudov U, Voynovan I, Gulustan B, Rodrigo L, Fiorini G, Perez-Aisa A, Tejedor-Tejada J, Tepes B, Vologzanina L, Mammadov E, Lerang F, Oglu QFV, Bakulina NV, Abdulkhakov R, Tatiana I, Butler TJ, Sarsenbaeva AS, Bumane R, Lucendo AJ, Romano M, Bujanda L, Abdulkhakov SR, Zaytsev O, Pabon-Carrasco M, Keco-Huerga A, Denkovski M, Huguet JM, Perona M, Nunez O, Pavoni M, Fadieienko G, Alekseenko S, Smith SM, Hernandez L, Kupcinskas J, Bordin DS, Leja M, Gasbarrini A, Gridnyev O, Cano-Catala A, Parra P, Moreira L, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg). Helicobacter. 2024 Jul-Aug;29(4):e13111. doi: 10.1111/hel.13111.

  PMID: 39001621 DERIVED

• Bujanda L, Nyssen OP, Ramos J, Bordin DS, Tepes B, Perez-Aisa A, Pavoni M, Castro-Fernandez M, Lerang F, Leja M, Rodrigo L, Rokkas T, Kupcinskas J, Jonaitis L, Shvets O, Gasbarrini A, Simsek H, Phull PS, Buzas GM, Machado JC, Boltin D, Boyanova L, Tonkic A, Marlicz W, Venerito M, Vologzanina L, Fadieienko GD, Fiorini G, Resina E, Munoz R, Cano-Catala A, Puig I, Garcia-Morales N, Hernandez L, Moreira L, Megraud F, Morain CO, Montes M, Gisbert JP; Hp-EuReg investigators; Hp-EuReg investigators. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance. Am J Gastroenterol. 2024 Apr 1;119(4):646-654. doi: 10.14309/ajg.0000000000002600. Epub 2023 Nov 17.

  PMID: 37983769 DERIVED

• Burgos-Santamaria D, Nyssen OP, Gasbarrini A, Vaira D, Perez-Aisa A, Rodrigo L, Pellicano R, Keco-Huerga A, Pabon-Carrasco M, Castro-Fernandez M, Boltin D, Barrio J, Phull P, Kupcinskas J, Jonaitis L, Ortiz-Polo I, Tepes B, Lucendo AJ, Huguet JM, Areia M, Jurecic NB, Denkovski M, Bujanda L, Ramos-San Roman J, Cuadrado-Lavin A, Gomez-Camarero J, Jimenez Moreno MA, Lanas A, Martinez-Dominguez SJ, Alfaro E, Marcos-Pinto R, Milivojevic V, Rokkas T, Leja M, Smith S, Tonkic A, Buzas GM, Doulberis M, Venerito M, Lerang F, Bordin DS, Lamy V, Capelle LG, Marlicz W, Dobru D, Gridnyev O, Puig I, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg). Gut. 2022 Dec 5:gutjnl-2022-328232. doi: 10.1136/gutjnl-2022-328232. Online ahead of print.

  PMID: 36591610 DERIVED

• Nyssen OP, Vaira D, Perez Aisa A, Rodrigo L, Castro-Fernandez M, Jonaitis L, Tepes B, Vologzhanina L, Caldas M, Lanas A, Lucendo AJ, Bujanda L, Ortuno J, Barrio J, Huguet JM, Voynovan I, Lasala JP, Sarsenbaeva AS, Fernandez-Salazar L, Molina-Infante J, Jurecic NB, Areia M, Gasbarrini A, Kupcinskas J, Bordin D, Marcos-Pinto R, Lerang F, Leja M, Buzas GM, Niv Y, Rokkas T, Phull P, Smith S, Shvets O, Venerito M, Milivojevic V, Simsek I, Lamy V, Bytzer P, Boyanova L, Kunovsky L, Beglinger C, Doulberis M, Marlicz W, Goldis A, Tonkic A, Capelle L, Puig I, Megraud F, Morain CO, Gisbert JP; European Registry on Helicobacter pylori Management Hp-EuReg Investigators. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg). Clin Gastroenterol Hepatol. 2022 Oct;20(10):2243-2257. doi: 10.1016/j.cgh.2021.12.025. Epub 2021 Dec 23.

  PMID: 34954341 DERIVED

• Nyssen OP, Perez-Aisa A, Tepes B, Castro-Fernandez M, Kupcinskas J, Jonaitis L, Bujanda L, Lucendo A, Jurecic NB, Perez-Lasala J, Shvets O, Fadeenko G, Huguet JM, Kikec Z, Bordin D, Voynovan I, Leja M, Machado JC, Areia M, Fernandez-Salazar L, Rodrigo L, Alekseenko S, Barrio J, Ortuno J, Perona M, Vologzhanina L, Romero PM, Zaytsev O, Rokkas T, Georgopoulos S, Pellicano R, Buzas GM, Modolell I, Gomez Rodriguez BJ, Simsek I, Simsek C, Lafuente MR, Ilchishina T, Camarero JG, Dominguez-Cajal M, Ntouli V, Dekhnich NN, Phull P, Nunez O, Lerang F, Venerito M, Heluwaert F, Tonkic A, Caldas M, Puig I, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). Am J Gastroenterol. 2021 Jun 1;116(6):1220-1229. doi: 10.14309/ajg.0000000000001246.

  PMID: 33840725 DERIVED

• Nyssen OP, Perez-Aisa A, Castro-Fernandez M, Pellicano R, Huguet JM, Rodrigo L, Ortun J, O, Gomez-Rodriguez BJ, Pinto RM, Areia M, Perona M, Nunez O, Romano M, Gravina AG, Pozzati L, Fernandez-Bermejo M, Venerito M, Malfertheiner P, Fernanadez-Salazar L, Gasbarrini A, Vaira D, Puig I, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg investigators. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. United European Gastroenterol J. 2021 Feb;9(1):38-46. doi: 10.1177/2050640620972615. Epub 2021 Feb 11.

  PMID: 33176617 DERIVED

• McNicholl AG, Bordin DS, Lucendo A, Fadeenko G, Fernandez MC, Voynovan I, Zakharova NV, Sarsenbaeva AS, Bujanda L, Perez-Aisa A, Vologzhanina L, Zaytsev O, Ilchishina T, Coba C, Lasala JP, Alekseenko S, Modolell I, Molina-Infante J, Ruiz-Zorrilla Lopez R, Alonso-Galan H, Moreno NF, Hinojosa J, Santaella I, Varela P, Gonzalez-Cordero PL, Barrio J, Dominguez-Jimenez JL, Nunez O, Alcedo J, Nyssen OP, Caldas M, Donday MG, Shvetz O, Megraud F, O'Morain C, Gisbert JP. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clin Gastroenterol Hepatol. 2020 Jan;18(1):89-98. doi: 10.1016/j.cgh.2019.03.048. Epub 2019 Apr 10.

  PMID: 30978536 DERIVED

Study Officials

• Javier Pérez Gisbert, MD

  Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Javier Pérez Gisbert, MD

CONTACT

+34 913093911; javier.p.gisbert@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Javier P. Gisbert MD

Study Record Dates

• First Submitted: December 19, 2014
• First Posted: December 31, 2014
• Study Start: June 1, 2013
• Primary Completion (Estimated): December 1, 2034
• Study Completion (Estimated): December 1, 2034
• Last Updated: October 2, 2024

Record last verified: 2024-10

Locations

SL (1); CZ (1); LA (1); RU (1); CH (1); GR (1); DE (1); TU (1); FI (1); BE (1); BU (1); IT (1); NO (1); SE (1); DK (1); ES (1); HU (1); UA (1); GB (1); CR (1); FR (1); NL (1); PL (1); PT (1); LI (1); RO (1); IE (1); AU (1)